Compare UiPath Inc (PATH) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs 10X Genomics Inc — how do they compare? UiPath Inc trades at $13.3 (market cap $6.81B), while 10X Genomics Inc trades at $79.5 (market cap $9.92B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and 10X Genomics Inc for 92 Days on average.
| PATH | TXG | |
|---|---|---|
Market Cap | $6.81B | $9.92B |
Volume | 22,766,109 | 9,372,166 |
Sector | Technology | Health |
52-Week High | $19.29 | $97.74 |
52-Week Low | $9.38 | $11.48 |
Typical Hold Time | 139 Days | 92 Days |
Enterprise Value | $5.61B | $9.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.07, down 0.23% on the day, amid a bearish technical signal and mixed earnings history. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while net income is expected to turn positive. Recent news highlights AI partnerships and product innovations, but the stock faces headwinds from cautious analyst sentiment and technical resistance.
The outlook for PATH is cautiously optimistic, with strong revenue growth and a path to profitability offering upside potential, but risks include execution challenges and competitive pressures. The consensus price target of $15.13 suggests moderate upside from current levels, though investor sentiment remains divided.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
